A high-dose version of Novo Nordisk’s type 2 diabetes drug Victoza, containing the active ingredient liraglutide, has been approved by the Food and Drug Administration (FDA) to treat obesity. The new diet drug will be marketed by Novo Nordisk under the brand name Saxenda. Like Victoza, the new weight loss treatment comes as in injectable drug and is intended for patients with a body mass index (BMI) of 30 or higher and at least one weight-related health condition, such as diabetes. Novo Nordisk believes Saxenda has the potential to be a blockbuster medication, generating sales of more than a billion dollars ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.